If you typed “Bodenxt” into Google, you are not the only one. The word looks like a brand name, but when you search for it, Google shows results for BioNxt. That is a small Canadian company that works on new ways to take medicine.
I could not find a company or product with the exact name “Bodenxt”. Because of that, this guide explains BioNxt, the closest match. If you meant a different brand, the facts below will not apply to it.
The Short Answer
BioNxt Solutions Inc. is a bioscience company. In simple words, it does not invent brand new drugs. Instead, it finds new ways to give medicines that already exist. Its main idea is a thin film that melts under your tongue. The company says this can be easier to take than a tablet or an injection.
Here are the key facts:
- The company is based in Vancouver, Canada.
- Its shares trade on the Canadian Securities Exchange under the symbol BNXT.
- Its main work happens in Germany and other parts of Europe.
- Its two best known projects are a film for multiple sclerosis and a film for semaglutide.
- It does not have an approved product on the market yet.
What Is BioNxt?
BioNxt Solutions Inc. was set up in 2017. At first, it was called XPhyto Therapeutics. In November 2022, it changed its name to BioNxt Solutions. The new name fits its new focus on drug delivery.
The company says it works in North America and Europe, and it puts most of its effort into getting approvals in European markets. It has a German subsidiary called Vektor Pharma TF GmbH. This is the place where much of its film testing has been done.
Over the years, the company has described many different projects. Older company profiles mention medical tests for infections, patches for the skin, and other health products. In recent news, however, the story is clear. BioNxt now focuses mainly on thin films, and it says it wants to grow from “a single product story” into a wider drug delivery company.
BioNxt describes three main platforms:
- Sublingual thin film: a small film that dissolves under the tongue.
- Transdermal patch: a patch that puts medicine through the skin.
- Oral tablet: a tablet with a special coating that protects it in the stomach.
The company says these platforms aim at autoimmune diseases, brain and nerve diseases, and healthy aging.
The Big Idea: Medicine That Melts Under Your Tongue
To understand BioNxt, you need to understand one simple idea. Most medicines are swallowed. After that, they travel through your stomach and gut before they reach your blood. On the way, stomach acid and enzymes can break some of the medicine down. Because of this, you may need a larger dose to get enough into your body.
A sublingual film works in a different way. “Sublingual” means “under the tongue”. You place the film under your tongue, and it dissolves in a short time. The medicine then passes through the thin skin inside your mouth and goes into your blood. Because it skips part of the gut, less medicine may be lost.
BioNxt says this method has three possible benefits:
- No needles. This matters for people who do not like injections.
- No swallowing. This matters for people who find it hard to swallow tablets.
- Better absorption. The company says the film can reduce the damage that enzymes cause in the gut.
Please remember that these are claims from the company. They are not proven in humans yet. Scientists need to run careful human studies before anyone can say the film works better than the tablet.
Project 1: A Film for Multiple Sclerosis (BNT23001)
The first project is called BNT23001. It is a sublingual film that contains cladribine, a medicine for multiple sclerosis (MS). MS is a long term disease where the immune system attacks the nerves. People with MS can have problems with movement, balance, and swallowing.
Cladribine is already approved in tablet form. The best known brand is Mavenclad. According to BioNxt, cladribine tablets made about 1.28 billion US dollars in global sales in 2024. The company wants to offer a melt-in-your-mouth option for people who find tablets hard to swallow.
What the early results show
In January 2026, BioNxt reported the final results of a study in pigs. In this study, the film gave about 40 percent more cladribine exposure than a normal tablet. The company reported an average exposure of 39.46 for the film and 28.11 for the tablet. The numbers use a unit called nanogram-hours per milliliter.
This is a good sign, but you should read it with care. A pig study is not a human study. Results in animals do not always repeat in people. The company itself says the next step is a study in humans.
Patents and next steps
BioNxt also reported that the European Patent Office decided to grant a patent for its cladribine film. The patent covers a special mix of cladribine with a sugar-like ingredient called cyclodextrin, together with materials such as starch and pullulan. The company says the patent is not limited to MS and can cover other autoimmune and brain diseases.
Because cladribine is already an approved medicine, the company expects its work to focus on showing that the film delivers the drug in a similar or better way than the tablet. News reports said that a first study in humans was planned for the second half of 2026. I could not find a report that this study has started, so check the company’s latest news for an update.
The company has also said it wants to test the same film idea for myasthenia gravis, another autoimmune disease where swallowing can be hard.
Project 2: A Film for Semaglutide (BNT24005)
The second project is newer and gets a lot of attention. Semaglutide is the medicine inside Ozempic, Wegovy, and Rybelsus. People use it for type 2 diabetes and weight loss. Today, most people take it as an injection, and there is also a daily tablet.
BioNxt wants to make a sublingual film version. Here is a short timeline:
- December 2024: The company announced it was developing a semaglutide film.
- June 2025: It started a feasibility study.
- September 2025: It reported that early tests at Vektor Pharma worked. The prototypes dissolved quickly, had an even quality, and had useful physical properties.
- May 2026: The program moved into a more serious development stage with a German partner called Gen-Plus GmbH.
Semaglutide is a peptide, which is a small chain of building blocks like a protein. Peptides are hard to give as pills because the gut can break them down. For this reason, the early tests were important. The company says they show that its thin film can carry this kind of medicine.
Still, this project is at an early stage. The company has said it plans more work on stability, larger scale production, and animal studies before it can think about human trials.
Other News: New Technology and New Ideas
BioNxt has also made some smaller moves:
- In February 2026, it signed a letter of intent to get a technology called a “drug chaperone”. The company says it could help its films work better and protect its ideas with patents. A letter of intent is only a first step, not a final deal.
- It has said it is working on a platform to send cancer medicine directly to tumors, so that healthy parts of the body get less of the drug.
- In mid 2026, a German finance site reported that the company hired outside advisers to help plan how to bring BNT23001 to market.
Why So Many People Watch the Company
There are two simple reasons.
First, the markets are very large. Semaglutide brought in more than 29 billion US dollars in sales in 2024, according to a German finance report. Cladribine tablets made over a billion. If a small company could take even a small part of such a market, that would be big for the company.
Second, the idea is easy to understand. Many people would prefer a film to a needle, and many patients struggle with pills. A product that fixes these small daily problems can have a real value.
How BioNxt Pays for Its Work
Research costs a lot of money, and BioNxt has no approved product to sell yet. So the company depends on money from investors and lenders. Here are some examples from the news:
- It has issued convertible debentures. These are loans that the lender can later change into shares.
- In early 2026, it paid back about 2.7 million Canadian dollars of debt by giving shares to its creditors. It issued 6,008,883 shares at a set price of 0.45 dollars each.
- In June 2026, it moved the due dates of several debentures to later dates.
- On July 31, 2026, it gave 750,000 stock options to insiders, consultants, and an employee.
None of this is unusual for a small biotech company. Still, it shows that the company needs to keep finding money while it waits for results.
Risks and Things to Keep in Mind
It is a good idea to see the full picture. Here are the main points that a careful reader should think about.
- No approved product yet. The company has results from labs and animals, but it still needs human studies and approval from health regulators.
- Early results can change. Many medicines look good in early tests and then fail later.
- The company needs money. Data websites and analysts note that the company has losses, and it has to raise funds again and again.
- Big competitors. Companies like Novo Nordisk sell semaglutide and have far more money and experience.
- The share price moves a lot. German finance news in 2026 reported a fall in the share price during the year, even after good news about its projects.
- Most news comes from the company. Many articles repeat company press releases. Look for independent sources when you can.
This article is for general information only. It is not financial or medical advice. If you think about buying shares, talk to a licensed adviser. If you have a health question, talk to your doctor.
How to Check the Latest News
Company news changes fast. If you want to follow BioNxt in a safe way, use these steps:
- Visit the company website, bionxt.com, for press releases.
- Check the Canadian filing site SEDAR+ for official documents.
- Look at the Canadian Securities Exchange page for the symbol BNXT.
- Compare more than one news source. Be careful with articles that use strong words like “breakthrough” for early results.
Final Thoughts
Bodenxt is most likely a different way to write BioNxt, and this is the company that Google connects to the word. BioNxt has an easy to understand goal: make existing medicines simpler to take. Its cladribine film for multiple sclerosis and its semaglutide film are the two projects to watch. Early results are promising, but they come mostly from the lab and from animals. The real test is still ahead, when the films are tried in people.
If you are curious about the company, follow its official news and read each announcement with a calm mind. Good news in early research is nice to see, but it is only one step on a long road.
Frequently Asked Questions
What is Bodenxt?
Bodenxt does not seem to be a real company or product name. When you search for it, Google shows results for BioNxt Solutions Inc., a Canadian drug delivery company. It works on thin films that dissolve under the tongue and on other ways to give medicine without needles or large tablets.
Is BioNxt’s medicine available in stores or pharmacies?
No. At the time of writing, BioNxt does not have an approved product on the market. Its two lead projects, the cladribine film for multiple sclerosis and the semaglutide film, are still in development. A new medicine must pass human studies and get approval from health regulators before people can buy it.
Is BioNxt a safe company to invest in?
Nobody can answer that for you, and this article cannot give financial advice. BioNxt is a small company with no approved product, and it has reported losses. Its share price has also moved up and down a lot. Anyone who is thinking about investing should read the official filings, think about the risks, and speak to a licensed financial adviser first.
